NOW IN A TABLET
–
SAME RELIABLE RESULTS AS URIBEL®CAPSULES
This product replaces Uribel® capsules. Tablet shown is not actual size.
NOW IN A TABLET
–
SAME RELIABLE RESULTS AS URIBEL® CAPSULES
This product replaces Uribel® capsules. Tablet shown is not actual size.
NOW IN A TABLET
–
SAME RELIABLE RESULTS AS URIBEL® CAPSULES
This product replaces Uribel® capsules. Tablet shown is not actual size.
NOW IN A TABLET
–
SAME RELIABLE RESULTS AS URIBEL® CAPSULES
This product replaces Uribel® capsules. Tablet shown is not actual size.
Chronic Urinary Tract Conditions

Chronic Urinary Tract Conditions

Symptoms1,2:

  • Pelvic pain or pressure (sometimes intense) triggered by a variety of factors, including stress
  • As the bladder starts to fill, there is pain (rather than discomfort) that gets worse until the patient urinates
  • A strong, painful urge to urinate many times a day

Laura is a working mom who doesn’t have time to deal with her urinary tract flare-ups, which recur often. The urinary pain and pressure can be a constant distraction.*

Uribel® Tabs Therapy

Uribel® Tabs contain both antispasmodic and analgesic agents to help relieve local symptoms of:
  • Pain
  • Inflammation
  • Hypermotility

Uribel Tabs help Laura focus on her busy life, not her symptoms. The analgesic and antispasmodic ingredients of Uribel Tabs help to alleviate the pain and pressure of her symptoms.*

*Hypothetical patient. Results may vary.

References

  1. Bosch PC, Bosch DC. Treating interstitial cystitis/bladder pain syndrome as a chronic disease. Rev Urol. 2014; 16(2):83-87.
  2. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of Interstitial Cystitis.
    https://www.niddk.nih.gov/health-information/urologic-diseases/interstitial-cystitis-painful-bladder-syndrome/symptoms-causes. Accessed June 2024.

The Uribel Tabs savings card is available to everyone.†

Patients with private insurance can use the Uribel Tabs savings card to offset the cost of a co-payment or coinsurance.

Patients without insurance coverage can use the Uribel Tabs savings card to receive a discount off the retail price of each prescription.

Patients with Medicare can use the Uribel Tabs savings card:

Medicare does not cover Uribel Tabs; therefore,

-Patients can use the Uribel Tabs savings card to receive a discount off the retail price of each prescription.

-Medicare patients are entitled to use the Uribel Tabs savings card if they are paying the full retail price for Uribel Tabs.

†Subject to eligibility. Terms and conditions apply.
DOWNLOAD THE SAVINGS CARD
Mission Pharmacal Company
San Antonio, TX 78230-1355
(210) 696-8400
This material is intended to provide basic information and is not medical advice. All medical advice, diagnosis, and treatment should be obtained from your physician. The product information provided in this site is intended for residents of the United States. Copyright © 2024 Mission Pharmacal Company. All rights reserved.
Important Safety Information:
Expand Close

INDICATIONS: Uribel® Tabs (methenamine 81.6 mg, benzoic acid 9.0 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, and hyoscyamine sulfate 0.12 mg) are indicated for the treatment of symptoms of irritative voiding, the relief of local symptoms (e.g., inflammation, hypermotility, pain) which accompany lower urinary tract infections, and for the relief of urinary tract symptoms caused by diagnostic procedures.

Important Safety Information

CONTRAINDICATIONS: Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered with certain medical conditions: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

WARNINGS: Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs, discontinue use immediately.

PRECAUTIONS: Uribel Tabs should be used with caution in:

  • patients who are intolerant of belladonna alkaloids or salicylates.
  • patients with gastric ulcers. Delay in gastric emptying could complicate management.
  • pregnant women. It is not known whether Uribel Tabs cause fetal harm or can affect reproductive capacity. Only use if clearly needed.
  • nursing mothers. Only use if clearly needed as methenamine and hyoscyamine are excreted in breast milk.
  • patients who require prolonged use. There have been no studies to establish the safety of long-term use in humans or animal studies to evaluate carcinogenic potential.
  • infants and young children as they are especially susceptible to the toxic effects of belladonna alkaloids.
  • elderly patients as they may experience excitement, agitation, drowsiness or confusion.

ADVERSE REACTIONS: Adverse reactions associated with Uribel Tabs include: rapid heartbeat, flushing, blurred vision, dizziness, drowsiness, difficult micturition, acute urinary retention, dry mouth, nausea, vomiting, and shortness of breath or trouble breathing.

Serious allergic reactions to this drug are rare. Patients should be instructed to seek immediate medical attention if they experience symptoms of a serious allergic reaction, including itching, rash, severe dizziness, swelling or trouble breathing.

This medication can cause urine and sometimes stools to turn blue to blue-green. This effect is harmless and will subside after medication is stopped, however, patients should be advised.

DRUG INTERACTIONS: Because Uribel Tabs can alter gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications such as:

  • urinary alkalizers
  • thiazide diuretics (may reduce the effectiveness of methenamine)
  • antimuscarinics (may intensify antimuscarinic effects of hyoscyamine)
  • antacids/antidiarrheals (may reduce absorption of hyoscyamine; may reduce effectiveness of methenamine).
    Doses of these medications should be spaced 1 hour apart from doses of Uribel Tabs.
  • antimyasthenics (concurrent use may further reduce intestinal motility)
  • ketoconazole (patients should be advised to take Uribel Tabs at least 2 hours after ketoconazole)
  • monoamine oxidase (MAO) inhibitors (may intensify antimuscarinic side effects)
  • opioids (may result in increased risk of severe constipation)
  • sulfonamides (may increase the danger of crystalluria)

Methylene blue inhibits a range of CYP isozymes in vitro (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5). Interactions may be more pronounced with narrow therapeutic margin drugs that are metabolized by one of these enzymes (e.g., digoxin, warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus. The clinical relevance of these in vitro interactions is unknown.

Please click here for full Prescribing Information.